Skip to main content

Table 1 Clinical characteristics of healthy subjects and asthmatics

From: Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment

Variables Healthy subjects Asthmatics p value
Subjects (male/female) 3 (0/3) 12 (2/10)  
Age (years) § 55 (42-67) 57 (38-67) 0.825
Disease duration (years) § 0 8 (0.5-20) na
Body Mass Index § 30.9 (24.1-34.9) 31.5 (19.4-41.4) 0.897
FVC (% pred.) # 118 ± 8 86 ± 6 0.035
FEV 1 /FVC # 0.85 ± 0.01 0.81 ± 0.03 0.61
PD20 (mg of methacholine) # neg. or not performed 0.13 ± 0.05 na
Documented SPT positivity 0 8¤  
  1. The baseline clinical characteristics of all subjects showed a statistically significant difference in FVC % predicted between the two groups, using a Student's t-test. No differences were seen in the other variables. A p value of < 0.05 was considered statistically significant (shown in bold).
  2. Abbreviations: FEV1 = forced expiratory volume in 1 sec; FVC = forced vital capacity; PD20 = provocative dose of methacholine producing a 20% decrease in FEV1; F E NO = fractional exhaled nitric oxide; SPT = skin prick test; na = not applicable; § = data presented as mean (range); # = data presented as mean ± standard error of the mean; = n = 10 (1 patient was negative, 1 patient was not tested) ¤ = 2 patients were negative, 2 patients were not tested, but had no clinical history of allergy.